- Home
- NXL
as 11-06-2025 3:56pm EST
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | HOUSTON |
| Market Cap: | 25.1M | IPO Year: | 2022 |
| Target Price: | $5.00 | AVG Volume (30 days): | 675.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.69 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.70 - $4.49 | Next Earning Date: | 11-07-2025 |
| Revenue: | $174,813 | Revenue Growth: | 16.42% |
| Revenue Growth (this year): | 38.28% | Revenue Growth (next year): | 185.71% |
Latest Nexalin Technology Inc. News
NXL Breaking Stock News: Dive into NXL Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel
GlobeNewswire
17 days ago
Nexalin’s DIFS™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer’s and Dementia Across Three Peer-Reviewed Studies
ACCESS Newswire
21 days ago
Nexalin Technology and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
GlobeNewswire
25 days ago
Nexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer’s and Traumatic Brain Injury Programs
GlobeNewswire
a month ago
Nexalin Technology Announces Attendance at the 2025 Maxim Growth Summit
Simply Wall St.
a month ago
Is Nexalin Technology (NASDAQ:NXL) In A Good Position To Deliver On Growth Plans?
MT Newswires
a month ago
Top Midday Gainers
MT Newswires
a month ago
Nexalin Technology Shares Rise After Alzheimer's Treatment Shows Positive Clinical Results
Compare NXL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NXL Nexalin Technology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.